Cantor Fitzgerald Suspends Neutral Rating on AtaiBeckley Inc
Cantor Fitzgerald suspends Neutral rating on AtaiBeckley Inc (NASDAQ:ATAI).
Stocks · News reference
AtaiBeckley Says Hart-Scott-Rodino Waiting Period For Merger With Eli Lilly Expired On Aug 28, 2026; UK Competition Authority Has No Further Questions On Merger As Of August 21, 2026
As previously disclosed, AtaiBeckley Inc. (the "Company") entered into an Agreement and Plan of Merger, dated as of July 15, 2026 (the "Merger Agreement"), with Eli Lilly and Company, an Indiana
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
'We Don't Know What the Risks Are': GLP-1 Pill Boom Fuels Hundreds of Apps, but Research Is Lagging
Oral GLP-1 weight-loss pills are driving a health-tech boom, but research on their safe use is struggling to keep pace.
Eli Lilly Receives FDA Approval For Olumiant In Pediatric Patients Aged 12 And Older With Severe Alopecia Areata
FDA approval supported by data from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe alopecia areata (AA)Treatment with Olumiant resulted in
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds
Nektar Therapeutics wins $90 million jury verdict against Eli Lilly in lawsuit over their rezpegaldesleukin licensing agreement.
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
Viking Therapeutics released positive maintenance dosing data for its GLP-1 drug candidate VK2735, causing the stock to surge 35%. The company is positioning itself as a potential competitor in the $100 billion weight loss drug market dominated by Eli Lilly and Novo Nordisk. Viking's dual GLP-1/GIP agonist could be the first oral formulation of its kind, with both injectable and oral versions available, offering advantages over current competitors.